Cargando…

Human castration resistant prostate cancer rather prefer to decreased 5α-reductase activity

Physiologically relevant steroid 5α-reductase (SRD5A) activity that is essential for dihydrotestosterone (DHT) biosynthesis in human castration-resistant prostate cancer (CRPC) has not been fully characterized yet. In this study to ascertain the potential SRD5A activity, we cultured two human CRPC c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosaka, Takeo, Miyajima, Akira, Nagata, Hirohiko, Maeda, Takahiro, Kikuchi, Eiji, Oya, Mototsugu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572449/ https://www.ncbi.nlm.nih.gov/pubmed/23429215 http://dx.doi.org/10.1038/srep01268

Ejemplares similares

Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?
por: Kosaka, Takeo, et al.
Publicado: (2014)

Reactive oxygen species induction by cabazitaxel through inhibiting Sestrin-3 in castration resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2017)

No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer
por: Kosaka, Takeo, et al.
Publicado: (2018)

Analysis of cabazitaxel‐resistant mechanism in human castration‐resistant prostate cancer
por: Hongo, Hiroshi, et al.
Publicado: (2018)

PKM2 under hypoxic environment causes resistance to mTOR inhibitor in human castration resistant prostate cancer
por: Yasumizu, Yota, et al.
Publicado: (2018)

Transumbilical laparo-endoscopic single site surgery for adrenal cortical adenoma inducing primary aldosteronism: initial experience
por: Miyajima, Akira, et al.
Publicado: (2011)

Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
por: Watanabe, Keitaro, et al.
Publicado: (2021)

Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma
por: Ide, Hiroki, et al.
Publicado: (2012)

Discovery of a new candidate drug to overcome cabazitaxel-resistant gene signature in castration-resistant prostate cancer by in silico screening
por: Hongo, Hiroshi, et al.
Publicado: (2021)

Vasohibin-1 as a novel microenvironmental biomarker for patient risk reclassification in low-risk prostate cancer
por: Kobayashi, Hiroaki, et al.
Publicado: (2017)

Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report
por: Yanai, Yoshinori, et al.
Publicado: (2019)

Complete response with early introduction of cabazitaxel in a patient with multiple lung metastases of castration-resistant prostate cancer following the early detection of metastases using liquid biopsy: a case report
por: Kosaka, Takeo, et al.
Publicado: (2019)

Cranial nerve palsy caused by metastasis to the skull base in patients with castration‐resistant prostate cancer: Three case reports
por: Yasumizu, Yota, et al.
Publicado: (2021)

Salvage focal brachytherapy in castration‐resistant prostate cancer with neuroendocrine differentiation after radiation therapy
por: Komori, Takahiro, et al.
Publicado: (2022)

Castration-resistant prostate cancer patient presenting with whole genome doubling with CDK-12 mutation
por: Baba, Yuto, et al.
Publicado: (2022)

Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer
por: Ito, Yujiro, et al.
Publicado: (2015)

Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2020)

Long term follow-up in patients with initially diagnosed low grade Ta non-muscle invasive bladder tumors: tumor recurrence and worsening progression
por: Kobayashi, Hiroaki, et al.
Publicado: (2014)

Complete Response to Bicalutamide Withdrawal Prolonged for Almost 2 Years in Patients With Metastatic Prostate Cancer()
por: Hongo, Hiroshi, et al.
Publicado: (2014)

A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report
por: Iwasawa, Tomohiro, et al.
Publicado: (2022)

IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer
por: Shigeta, Keisuke, et al.
Publicado: (2023)

Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin
por: Ide, Hiroki, et al.
Publicado: (2014)

Lymphovascular invasion status at transurethral resection of bladder tumors may predict subsequent poor response of T1 tumors to bacillus Calmette-Guérin
por: Fukumoto, Keishiro, et al.
Publicado: (2016)

Influence of physician years on urological journal publication productivity among Japanese urologists
por: Niwa, Naoya, et al.
Publicado: (2016)

A Case of Bladder Cancer after Radiation Therapy for Prostate Cancer
por: Kaburaki, Naoto, et al.
Publicado: (2014)

Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel
por: Kosaka, Takeo, et al.
Publicado: (2018)

Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study
por: Matsushima, Masashi, et al.
Publicado: (2010)

Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer
por: Hagiwara, Masayuki, et al.
Publicado: (2018)

Impact of pegfilgrastim as primary prophylaxis for metastatic castration-resistant prostate cancer patients undergoing cabazitaxel treatment: an open-label study in Japan
por: Kosaka, Takeo, et al.
Publicado: (2019)

Genomic analysis of aggressive ductal adenocarcinoma of the prostate
por: Kobayashi, Hiroaki, et al.
Publicado: (2022)

Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report
por: Hongo, Hiroshi, et al.
Publicado: (2020)

Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer
por: Ide, Hiroki, et al.
Publicado: (2013)

Comparison of continence outcomes of early catheter removal on postoperative day 2 and 4 after laparoscopic radical prostatectomy: a randomized controlled trial
por: Matsushima, Masashi, et al.
Publicado: (2015)

Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model
por: Tamura, Koetsu, et al.
Publicado: (2015)

Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers
por: Fukumoto, Keishiro, et al.
Publicado: (2016)

A Case of Bladder-Inverted Papilloma after Brachytherapy for Prostate Cancer
por: Ezaki, Taisuke, et al.
Publicado: (2014)

Squamous cell carcinoma of the prostate with SMARCA4 alteration in a Japanese patient
por: Kaneko, Yuta, et al.
Publicado: (2022)

The first Japanese case of intraductal cancer of the prostate with checkpoint kinase 2 mutation
por: Hongo, Hiroshi, et al.
Publicado: (2022)

Initial experience of transumbilical laparoendoscopic single-site surgery of partial adrenalectomy in patient with aldosterone-producing adenoma
por: Yuge, Kazuyuki, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_i8ub8633es04k7782eusf1cv9d